Engflag

Acemen

Quick links to important sections

Acemen

Acemen_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acemen

Property Description
Active Ingredient Captopril
Form Tablets (Scored)
Pharmacological Class Angiotensin-Converting Enzyme (ACE) Inhibitor
General Purpose To reduce high blood pressure
Origin Synthetic (Non-prodrug)

What Type of Medicine is Acemen (Captopril)?

Acemen is a prescription-only medication whose active ingredient is Captopril, classifying it as a potent Angiotensin-Converting Enzyme (ACE) Inhibitor and an Antihypertensive Agent. This pharmacological classification defines Acemen as an established tool for supporting cardiovascular function by managing blood pressure. The substance Captopril is characterized as a synthetic compound and a non-prodrug, which is a significant L-proline derivative.

Composition and Physical Form of Acemen

Acemen is a single-product drug containing only the active ingredient Captopril, presented for oral administration in the form of scored tablets. This feature allows for the convenient division of the tablet, giving prescribers flexibility when adjusting therapeutic regimens. This medication is manufactured using precise pharmaceutical excipients that form the solid vehicle for the compressed tablet form. As an ACE inhibitor, Captopril is clinically recognized for its essential role in reducing high blood pressure. This means the drug directly helps to stabilize circulatory function in adults.

How Does Acemen Generally Help the Body?

Acemen's general purpose is to lower high blood pressure by promoting vasodilation, easing the burden on the heart and blood vessels. The drug achieves this benefit by causing Inhibition of Angiotensin-Converting Enzyme (ACE), which effectively suppresses the Renin-Angiotensin-Aldosterone System (RAAS). This suppression blocks the production of the potent vasoconstrictor Angiotensin II. Pharmacological studies confirm this action reliably leads to a reduction in the constriction of arteries and, consequently, a measurable decrease in pressure within the vascular system, demonstrating how the medication helps the heart work more efficiently.

What side effects are possible with Acemen?

Possible Side Effects and Safety Information

Acemen (Captopril), an Angiotensin-Converting Enzyme (ACE) inhibitor, is associated with a distinct profile of officially documented adverse reactions and safety risks. The most clinically significant and potentially fatal serious adverse reaction is Angioedema, which involves swelling of the face, extremities, lips, tongue, and/or larynx. Regulatory documents indicate that this reaction may occur at any time during treatment.

Commonly reported adverse reactions, classified as Common, often relate to the Nervous System and the Respiratory System. These include a persistent, non-productive cough, which typically resolves after discontinuing the medicine, dizziness, and an altered sense of taste impairment (dysgeusia). Gastrointestinal effects such as nausea, vomiting, and diarrhea are also common.

Less frequent, or Uncommon, effects may include hypotension (low blood pressure) and palpitations. Symptomatic hypotension is more likely to occur during the initial phase of treatment or in volume-depleted patients. Rare but serious systemic adverse reactions documented in regulatory sources include Neutropenia/Agranulocytosis (blood disorders) and Renal Failure (renal and urinary disorders).

Regarding population safety, the use of Acemen during the second and third trimesters of pregnancy is strictly contraindicated due to the officially documented risk of fetal injury and death. Furthermore, individuals with pre-existing renal impairment or certain conditions like Collagen Vascular Disease are at an increased risk for serious blood and kidney-related adverse reactions.

Overdose and Emergency Response

Overdose and when to seek help

This information describes the documented overdose manifestations and mandated emergency actions for Acemen (Captopril), based strictly on official government regulatory documents.

Documented Manifestations and Severe Outcomes

An overdose is primarily documented to cause severe hypotension (a profound drop in blood pressure), which may lead to the development of shock or renal failure. Other recognized manifestations listed in regulatory information include lethargy, bradycardia (slow heart rate), emesis (vomiting), and electrolyte disturbance.

Required Emergency Actions

Immediate medical attention is required for any suspected overdose. Emergency services must be contacted immediately if the individual shows signs of a severe outcome, such as having collapsed, experiencing a seizure, having trouble breathing, or cannot be awakened.

Management described in official labeling is symptomatic and supportive, as no specific antidote is known. Procedures include placing the patient in a supine position and administering fluids and sodium supplements to manage hypotension. Atropine administration is described for treating bradycardia, and haemodialysis may be considered for drug elimination.

Therapeutic Uses of Acemen

Acemen (generic name) is a medication generally applied across domains where additional symptomatic support is needed. It is considered relevant for a variety of conditions characterized by periods of heightened symptoms.

It is commonly used to help with managing glaucoma and idiopathic intracranial hypertension, where it may assist with symptoms linked to organ-specific functional stress and supports the patient during difficult episodes by easing distress. The medicine is also considered relevant for easing symptoms associated with acute mountain sickness (altitude sickness) and may be part of symptomatic management for conditions involving episodic or fluctuating manifestations like certain types of epilepsy. Furthermore, in clinical settings that involve acute or unstable symptom patterns, it is applied as adjunctive therapy in managing symptoms related to congestive heart failure, assisting with symptoms related to systemic imbalance.

Its therapeutic use supports patients during episodes of heightened discomfort. “Its overall role is to provide supportive relief when symptoms interfere with routine activities.” Acemen is considered relevant in contexts involving heightened systemic burden and its use contributes to easing the overall symptom load across various conditions presenting with acute episodes.

Quick Fact: Relief for Symptoms Related to Systemic Imbalance

Regulatory References

  1. NIH StatPearls overview on Acetazolamide

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Acemen (Captopril)

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adults with established indications, including Hypertension, Heart Failure, Left Ventricular Dysfunction Post-Myocardial Infarction, and Diabetic Nephropathy.

Populations for whom use is contraindicated:

  • Patients with a history of Angioedema (swelling) related to previous ACE Inhibitor therapy, or with hereditary/idiopathic angioedema.
  • Patients with known Hypersensitivity to Captopril or any other ACE Inhibitor.
  • Patients in the Second and Third Trimesters of Pregnancy. Use in the first trimester is not recommended.
  • Patients receiving a Neprilysin Inhibitor (or within 36 hours of the last dose).
  • Patients receiving Aliskiren who also have Diabetes Mellitus or Renal Impairment.

Age-related eligibility rules:

  • Pediatric use (Children and Adolescents) is formally documented as not fully established regarding efficacy and safety, requiring close medical supervision.

Condition-specific eligibility rules:

  • Use is conditional and often requires lower initial dosing for patients with severe Impaired Renal Function, Bilateral Renal Artery Stenosis, or volume-depleted Heart Failure.
  • Caution is required for patients with Collagen Vascular Disease combined with renal impairment.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

  • Contraindicated, Not Recommended, Use Not Established, Use with Caution.

Regulatory basis:

  • Governmental regulatory documents (e.g., EMA SmPC, FDA Prescribing Information).

Connection to the overall eligibility profile (2–4 sentences): The regulatory documents structure the eligibility profile of Acemen (Captopril) by formally designating populations as either contraindicated, not recommended, or requiring restricted use. This is based on established risks associated with the ACE inhibitor class (e.g., angioedema history), risk during physiological states (e.g., pregnancy), and insufficient data for certain populations (e.g., children). This framework strictly defines who is officially permitted to use the medicine versus who is formally excluded.

What should I know about interactions with other medicines?

Acemen (Captopril) has officially documented interaction patterns that primarily relate to cardiovascular and electrolyte balance, as detailed in government regulatory documents. These constraints identify mandatory prohibitions and specific pharmacokinetic effects.

Formal Prohibitions and Timing Rules

Co-administration with Sacubitril/Valsartan is strictly prohibited, requiring a mandatory 36-hour separation period between taking either medicine to mitigate the risk of severe outcomes. Similarly, co-administration with the direct renin inhibitor Aliskiren is officially contraindicated for patients with diabetes or those with moderate-to-severe renal impairment (GFR <60 mathrm~mL/mathrmmin/1.73 mathrm~m^2).

Pharmacodynamic and Exposure Outcomes

Interactions with agents that manage fluid or potassium balance may result in hyperkalemia (elevated serum potassium), specifically when taken alongside Potassium-Sparing Diuretics or potassium supplements. Concomitant use with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may officially reduce Captopril’s antihypertensive effect and increases the risk of renal function deterioration. Furthermore, co-administration with Lithium can result in reduced clearance of Lithium, leading to increased drug exposure. Certain agents like mTOR Inhibitors are noted to increase the risk of angioedema.

Interaction Contexts and Constraints

The official drug label documents a reduction in Captopril absorption by 30% to 40% when administered with food. A population-specific consideration notes that the risk of bone marrow suppression (neutropenia) is heightened in patients with pre-existing renal dysfunction or collagen vascular disease.

Mechanism of Action

How Acemen Works

The mechanism of action for Acemen (Acemetacin) is mediated by its active metabolite. Acemetacin functions as a prodrug that undergoes metabolic conversion to indomethacin, which is responsible for the compound's primary pharmacodynamic activity.

Molecular Targets and Pathway Modulation

The active metabolite exerts its effect through the non-selective inhibition of the cyclooxygenase (COX) enzyme system, affecting both COX-1 and COX-2 isoforms. This interaction reduces the conversion of arachidonic acid into pro-inflammatory mediators, primarily the prostaglandins. This modification represents an early molecular step in the eicosanoid cascade, resulting in a reduction in prostaglandin synthesis at the site of action.

Mechanistic Consequences

Beyond direct enzyme inhibition, the drug's activity leads to the modulation of various cellular processes. It is involved in influencing the regulation of pro-inflammatory cytokine release from specific cell types, such as neutrophils and macrophages. This secondary engagement within local biochemical feedback loops affects signaling pathways implicated in heightened physiological responses, contributing to system-level physiological modulation.

Dosage and Administration Information

How to Use Acemen (Captopril)

Acemen is a prescription medication used strictly according to official guidelines concerning its administration route, dosing, and schedule. The primary focus of use is adherence to the required timing and dose adjustments specified in prescribing information.

Administration and Timing

Acemen is taken exclusively via the oral route (by mouth) as a scored tablet. To ensure maximum absorption, the tablets must be taken on an empty stomach, specifically one hour before a meal.

Treatment begins with a low dose and is subject to gradual dose titration, typically over several weeks, until the appropriate maintenance dose is achieved. The scored nature of the tablets allows for precise division to facilitate this low initial dosing.

Standard Labeled Dosing Regimens

Acemen is typically administered two or three times daily to maintain consistent control. The dosage varies based on the approved use, with specific starting, maintenance, and maximum daily dose limits.

Condition Typical Initial Dosing Range Target/Maintenance Dose Range
Hypertension 6.25 mg to 25 mg (2–3 times daily) 25 mg to 150 mg (2–3 times daily)
Heart Failure 6.25 mg to 12.5 mg (2–3 times daily) 50 mg (3 times daily)

Population-Specific Adjustments

Official instructions require dose modifications for specific patient populations:

  • Renal Impairment: The initial dose must be reduced in patients with decreased kidney function, and subsequent increases must be done carefully under supervision.
  • Older Adults: A lower initial starting dose (e.g., 6.25 mg twice daily) should be considered.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acemen (Captopril)

This section provides an overview of the official research evidence for Acemen (Captopril), describing the types of studies conducted and what their findings indicate, without offering any clinical advice or interpretation. Research focuses on what has been observed in studies and what data show patterns related to certain conditions.

Evidence for Use in Managing High Blood Pressure (Hypertension)

Research exploring the active ingredient in Acemen, Captopril, was studied for its application in high blood pressure (hypertension) using various designs, including Randomized Controlled Trials (RCTs) and large observational settings. These research scenarios focused on monitoring changes in the key biomarker of blood pressure, specifically the Systolic and Diastolic Blood Pressure (SBP/DBP) numbers. Studies also examined long-term Cardiovascular Outcomes, such as the frequency of major events like stroke or heart attack, in adults, including those with pre-existing conditions like coronary heart disease.

Research describes patterns related to measurable shifts in the blood pressure biomarker, with findings generally aligning across multiple trial settings. Long-term observational and regulatory analyses tracked the frequency of major cardiovascular events. The research supporting this application contributes to the broader evidence landscape often characterized by High certainty.

However, data for certain groups remain insufficient. Comparative evidence is still being explored against newer classes of medicines, particularly in specific populations. Furthermore, the evidence derived from settings with varying symptom burdens provides limited insight into very rapid management of acute blood pressure issues.

Evidence for Use in Managing Heart Failure and Post-Heart Attack Recovery

Research exploring the active ingredient in Acemen was studied for its application in Heart Failure with Reduced Ejection Fraction (HFrEF) and recovery following a Myocardial Infarction (heart attack), utilizing large-scale, long-term Placebo-Controlled RCTs. These studies were used in research exploring how functional measures and overall outcomes related to physical discomfort evolved in the observed populations. Outcomes monitored included changes in survival rates and the frequency of Hospitalization due to heart failure. Studies also examined structural changes in the heart muscle, known as Ventricular Remodeling.

For those with HFrEF, trials tracked survival profiles over several years, reporting patterns observed in the studies related to hospitalization events and functional scores. Similarly, studies conducted during periods following a heart attack were observed in patients who had already developed measurable reduced heart function. Research describes how these outcomes evolved over several years of observation.

A key limitation is that in many of the initial controlled trials, Captopril was studied for HFrEF as part of a regimen where patients were also receiving other established therapies. Because of this, comparative evidence is lacking for the effects of Captopril when used alone (monotherapy) for HFrEF. Also, the data gathered after a heart attack primarily reflects stable patients with reduced heart function, meaning the research does not fully establish its profile in patients with near-normal heart function immediately after the event.

Evidence for Kidney Protection in Type 1 Diabetes (Diabetic Nephropathy)

Research exploring the active ingredient in Acemen was studied for its application in Diabetic Nephropathy (a kidney complication in Type 1 Diabetes) and evaluated in multi-year, controlled trials. These studies primarily focused on outcomes related to physiological strain or stress, specifically monitoring changes in kidney function markers. Researchers examined the frequency of patients reaching a key kidney endpoint, such as the doubling of serum creatinine levels, and monitored levels of urine protein excretion (proteinuria) over long follow-up durations.

Findings describe patterns observed in the studies over time, particularly regarding the progression of kidney endpoints in the observed populations with established complications. The research also highlights changes measured during the study period in proteinuria levels. This research provides context but not individual predictions about the progression of kidney disease.

The available research is specific to the context of Type 1 Diabetes and patients who already have significant kidney complications. Because of this, the results apply only to the populations studied, and the evidence quality may vary across studies when considering other forms of chronic kidney disease.

Long-Term Studies and Durability of Research Findings

The evidence base for Captopril (the active ingredient), especially in cardiovascular contexts, includes data derived from trials with extended follow-up durations, often spanning two to five years. This research contributes to the broader evidence landscape by exploring outcomes related to physiological strain or stress over defined time intervals. These long-term studies help show what has been observed so far regarding outcomes related to the frequency of cardiovascular events and hospitalizations. The research supporting the core indications is generally derived from these multi-year observation periods. Long-term outcomes are not fully established beyond the observed trial durations, and continued research is ongoing to track results as patients age and treatment options evolve.

Research in Specific Populations and Patient Groups

Studies have been conducted across various adult patient groups, including those with differing degrees of impaired renal function and specific comorbidities. For example, research has explored the use of Captopril in patients with Type 1 Diabetes who had established kidney damage, which represents a highly specific patient group.

Research has also examined temporary physiological imbalance related to Captopril (the active ingredient) in non-systemic areas, such as studies focusing on changes in Intraocular Pressure (IOP) in adults with Primary Open Angle Glaucoma. This research, however, involved follow-up durations that were limited (often measured in hours) and sample sizes were modest. Consequently, certainty remains low for this application, and more long-term data are still emerging.

Key Limitations and Areas of Research Uncertainty

Despite the significant number of large-scale studies, there are still areas where the evidence is limited. One key research limitation is that the findings from the landmark heart failure trials often relied on the use of Captopril alongside other therapies, meaning comparative evidence is lacking for its use as a single treatment. Furthermore, the data for certain groups remain insufficient, particularly for outcomes in the most severely ill heart failure patients. Research also needs to provide further clarity on the mechanism behind the observed findings in the smaller, short-term studies related to intraocular pressure. The study results reflect the specific conditions under which they were conducted, and research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Acemen (FAQ)

Q: How quickly should I expect Acemen to start working?

A: Official product information indicates that the maximum reduction in blood pressure usually occurs about 60 to 90 minutes after taking an individual dose. However, the full therapeutic benefit may take longer to achieve, with maximal effects potentially requiring several weeks of consistent therapy.

Q: Why do some people say Acemen made them feel tired?

A: Regulatory safety documents report common adverse effects such as dizziness and headache, and drowsiness as a rare side effect. These effects on the central nervous system, such as dizziness and drowsiness, are documented in regulatory sources as potential factors related to feelings of tiredness.

Q: Are there any known side effects that affect sleep when taking Acemen?

A: Yes, official documentation lists sleep disorders as a common psychiatric undesirable effect. Information regarding changes in sleep patterns can be discussed with a healthcare professional.

Q: Is it normal to have mild stomach upset after taking Acemen?

A: Regulatory data on adverse reactions show that gastrointestinal effects, including nausea, vomiting, and diarrhea, are commonly reported. Since adverse reaction data reports these effects as common, these are known and documented effects in the official safety profile.

Q: Can elderly patients take Acemen without special monitoring?

A: Official instructions specify that a lower initial starting dose should be considered for older adults. Careful dose titration (gradual adjustment) and medical supervision are often part of the prescribed regimen for all patients, particularly older adults.

Q: How long does Acemen stay in your system after the last pill?

A: According to pharmacokinetic data, over 95% of the absorbed dose of the active ingredient is typically eliminated from the body in the urine within 24 hours. This elimination process is primarily carried out through the urine.

Q: Can Acemen cause any changes in mood or behavior?

A: Yes, regulatory documents list effects such as sleep disorders as common undesirable effects. More rarely, adverse effects like confusion and depression have also been reported in official documentation.

Q: What is the typical duration of treatment with Acemen?

A: Acemen is officially indicated for the treatment of chronic conditions, such as high blood pressure and heart failure. These conditions are often managed with long-term therapy. Clinical studies have often involved following patients for several years, in some cases up to five years.

Q: Can I take other pain relievers while using Acemen?

A: Official interaction warnings specifically state that taking Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may reduce the blood pressure lowering effect of Acemen and increase the risk of kidney problems. The official documentation warns about interactions with NSAIDs, but it does not formally address all other types of pain relievers.

Q: Why is Acemen sometimes taken for different conditions?

A: The drug is officially indicated for several conditions, including Hypertension, Heart Failure, Left Ventricular Dysfunction after a heart attack, and Diabetic Nephropathy. This is due to its specific mechanism of action in blocking the Renin-Angiotensin-Aldosterone System (RAAS), which benefits the body in multiple cardiovascular and renal contexts.

Q: Is Acemen considered a strong medication?

A: The active ingredient in Acemen, Captopril, is classified in official documents as a potent Angiotensin-Converting Enzyme (ACE) Inhibitor. This classification reflects its powerful pharmacological action within the body's systems.

Q: Why is the research on Acemen still being discussed in medical circles?

A: Official research documents indicate limitations, such as a lack of comparative evidence for its use as a single treatment in heart failure. Additionally, data for specific patient subgroups may still be insufficient, which prompts continuous research and ongoing discussion within the medical community.

Q: Can you drive or operate machinery while taking Acemen?

A: Official information indicates that caution is necessary when performing tasks such as driving or operating heavy machinery. This is because common adverse reactions like dizziness or tiredness may impair abilities, particularly when starting treatment or when the dosage is changed.

How should Acemen be stored and disposed of?

How to Store and Dispose of Acemen?

The storage of Acemen (Captopril tablets) must adhere strictly to official regulatory conditions to ensure stability and integrity.

Storage Requirements

Acemen must be stored at controlled room temperature, typically 20 C to 25 C. It is mandatory to keep the tablets in their original container and ensure the container is tightly closed to protect the contents from moisture and excess heat. Storage in environments such as a bathroom is prohibited. The medication must be kept out of the sight and reach of children using a child-resistant closure.

Disposal Instructions

Unused or expired Acemen should not be flushed down the toilet or disposed of in household trash. Official guidance recommends utilizing a formal drug take-back program or consulting a pharmacist for specific disposal instructions to ensure proper handling of pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Acemen found in:

A-Z Index: